2251-78-7

Basic information

• Product Name: 2H-Benzimidazol-2-one, 1,3-dihydro-4-(trifluoromethyl)-
• Synonyms: 4-trifluoromethyl-1,3-dihydro-benzoimidazol-2-one;4-Trifluormethyl-benzimidazolon-(2)-3H
• CAS NO: 2251-78-7
• Molecular Formula: C8H5F3N2O
• Molecular Weight: 202.13300
• Mol File: 2251-78-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2H-Benzimidazol-2-one, 1,3-dihydro-4-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Benzimidazol-2-one, 1,3-dihydro-4-(trifluoromethyl)-(2251-78-7)
• EPA Substance Registry System: 2H-Benzimidazol-2-one, 1,3-dihydro-4-(trifluoromethyl)-(2251-78-7)

Safety Data

• Hazardous Substances Data: 2251-78-7(Hazardous Substances Data)

Usage

Heterocyclic compound

Contains a benzimidazole ring

Trifluoromethyl group

Enhances biological activity and metabolic stability of drug molecules
Mainly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds
Potential applications in materials science and as a synthetic intermediate in organic synthesis

Upstream product

• 88-17-5 2-(trifluoromethyl)benzenamine 
• 444-93-9 (E)-2-(hydroxyimino)-N-(2-(trifluoromethyl)phenyl)acetamide 
• 391-12-8 7-trifluoromethylisatin 
• 313-12-2 2-amino-3-(trifluoromethyl)benzoic acid 
• 360-60-1 3-(trifluoromethyl)benzene-1,2-diamine 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 1075753-27-3 2-chloro-4-(trifluoromethyl)-1H-benzo[d]imidazole 

Relevant articles and documents

Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof

The invention discloses a benzenesulfonamide compound represented by a general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. Compared with the prior art, the benzenesulfonamide compound disclosed by the invention can be used as an isocitrate dehydrogenase 2 (IDH2) mutant inhibitor. According to the invention, pharmacological experiment results show that the compound disclosed by the invention has an obvious inhibiting effect on the activity of an IDH2 mutant (mIDH2), can effectively inhibit the process of catalyzing alpha-ketoglutaricacid to generate 2-hydroxyglutaric acid by mIDH2, and can be used for preventing and/or treating various related diseases including cancers and the like caused by IDH2 mutation.